Fatty liver screening: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
==Screening== | ==Screening== | ||
Per the American Gastroenterological Association (AGA) in | Per the American Gastroenterological Association (AGA) in 2021<ref name="pmid34602251">{{cite journal| author=Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E | display-authors=etal| title=Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease. | journal=Gastroenterology | year= 2021 | volume= 161 | issue= 5 | pages= 1657-1669 | pmid=34602251 | doi=10.1053/j.gastro.2021.07.049 | pmc=8819923 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34602251 }} </ref>, screening should be: | ||
* Diabetes mellitus Type 2 | * Diabetes mellitus Type 2 | ||
* 2 or more metabolic risk factors (entral obesity, high triglycerides, low HDL cholesterol, hypertension, prediabetes, or insulin resistance) | * 2 or more metabolic risk factors (entral obesity, high triglycerides, low HDL cholesterol, hypertension, prediabetes, or insulin resistance) | ||
* Excessive alcohol intake | * Excessive alcohol intake | ||
* Steatosis on any imaging modality or elevated aminotransferases | * Steatosis on any imaging modality or elevated aminotransferases | ||
Latest revision as of 16:57, 17 April 2023
|
Fatty Liver Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fatty liver screening On the Web |
|
American Roentgen Ray Society Images of Fatty liver screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Screening
Per the American Gastroenterological Association (AGA) in 2021[1], screening should be:
- Diabetes mellitus Type 2
- 2 or more metabolic risk factors (entral obesity, high triglycerides, low HDL cholesterol, hypertension, prediabetes, or insulin resistance)
- Excessive alcohol intake
- Steatosis on any imaging modality or elevated aminotransferases
Per the American Association for the Study of Liver Diseases (AASLD) in 2023[2]:
- "All patients with hepatic steatosis or clinically suspected NAFLD based on the presence of obesity and metabolic risk factors should undergo primary risk assessment with FIB-4."
References
- ↑ Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E; et al. (2021). "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease". Gastroenterology. 161 (5): 1657–1669. doi:10.1053/j.gastro.2021.07.049. PMC 8819923 Check
|pmc=value (help). PMID 34602251 Check|pmid=value (help). - ↑ Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D; et al. (2023). "AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease". Hepatology. doi:10.1097/HEP.0000000000000323. PMID 36727674 Check
|pmid=value (help).